Aptinyx (NASDAQ:APTX) completed enrollment for its Phase 2 study of NYX-783 for the treatment of post-traumatic stress disorder (PTSD).
The 160 enrolled patients were randomized to receive either placebo, 10 mg of NYX-783 or 50 mg of NYX-783, administered orally, once-daily for four consecutive weeks.
The trial’s primary efficacy endpoint is the change in clinician-administered PTSD scale for the DSM-5 total score and sub-scores from baseline to the end of the four-week treatment period.
“The completion of enrollment in our Phase 2 exploratory study of PTSD represents an important clinical development milestone for our company,” Norbert Riedel, Aptinyx’s president and CEO, said in a statement.
“We look forward to completing this study in the coming months and evaluating the data to determine the most appropriate next steps in development to address the unmet need in PTSD,” he added.
Data from the trial are expected in late 2020.
